According to our new research study on “Mononucleosis Diagnostic Market Forecast to 2031 -Global Analysis - by Type, End User, and Geography,” the market is anticipated to grow from US$ 151.44 million in 2023 and is projected to reach US$ 222.15 million by 2031; it is expected to register a CAGR of 4.9% during 2023-2031. High risk among the adolescent population, and the rising health awareness and knowledge about mononucleosis are contributing to the growing mononucleosis diagnostic market size. However, the low accuracy of existing diagnostic tests hampers the mononucleosis diagnostic market growth. Further, advancements in molecular diagnostics in mononucleosis diagnostic are expected to bring in new mononucleosis diagnostic market trends in the coming years.
In terms of revenue, North America dominated the mononucleosis diagnostic market in 2023. It is estimated to dominate the global market during the forecast period. The US is the largest market for mononucleosis diagnostics in the world, and it is estimated to dominate the market during the forecast period as well. The mononucleosis diagnostic market growth in the US is attributed to technological advancements, increased awareness, and a constant need for effective disease management strategies. According to the National Institutes of Health, the US records ~125,000 cases of infectious mononucleosis every year.
Owing to such a high number, the awareness of the mononucleosis caused by the Epstein-Barr virus (EBV) is also on the rise in the country, which bolsters the demand for rapid and accurate diagnostic test kits, consumables, and services. Various testing methods adopted by healthcare providers in the country include serological tests based on antibody detection and molecular tests focused on viral DNA identification. The competitive landscape of the mononucleosis diagnostics market in the US is dominated by companies such as Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers. These companies invest in innovation and collaborations to enhance their product offerings and expand their market presence.
Mononucleosis Diagnostic Market Analysis
Development of Point-of-Care Testing to Provide Market Opportunities in Future
POC testing allows for rapid diagnosis at or near the site of patient care, enabling healthcare providers to make immediate clinical decisions and improve patient outcomes. Traditional laboratory tests often require hours or days to generate results, which can delay treatment and worsen symptoms. In contrast, POC tests can deliver results within minutes, facilitating timely intervention. The rapid turnaround is especially crucial for conditions such as mononucleosis, as early diagnosis can reduce complications and enhance patient comfort. POC testing can be implemented in various healthcare settings, including outpatient clinics, emergency departments, and home care settings.
The accessibility is particularly beneficial in areas with limited laboratory infrastructure or in rural regions with insufficient healthcare resources. Bringing diagnostic capabilities closer to patients in the form of POC testing ensures that more individuals receive timely diagnoses and appropriate care, thereby broadening the reach of healthcare services. Moreover, this type of testing promotes greater engagement, as patients can receive their results quickly and discuss the next steps with their healthcare providers.
POC testing can be more cost-effective compared to traditional laboratory testing as they don't need extensive laboratory infrastructure, in turn lowering the overall costs for healthcare systems. The affordability of mononucleosis testing further drives its accessibility to a broader range of patients, especially in underserved populations. Recent advancements in biosensors and microfluidic technologies are driving the development of more sophisticated POC tests with improved sensitivity and specificity.
These innovations ensure the reliability of POC tests in detecting mononucleosis. Mononucleosis diagnostic market players offering POC test kits include SEKISUI Diagnostics (OSOM Mono Test), Abbott (Clearview Mono), and Cardinal Health [Cardinal Health MONO (Mononucleosis) II Rapid Test]. Thus, the development of POC testing generates substantial growth opportunities for the mononucleosis diagnostics market players.
Mononucleosis Diagnostic Market Report Segmentation Analysis
Key segments that contributed to the derivation of the mononucleosis diagnostic market analysis are type and end user.
Mononucleosis Diagnostic Market: Competitive Landscape and Key Developments
Abbott Laboratories, Arlington Scientific Inc, Bio-Rad Laboratories Inc, Cardinal Health Inc, Meridian Bioscience Inc, Sekisui Diagnostics LLC, Thermo Fisher Scientific Inc, QuidelOrtho Corp, F. Hoffmann-La Roche Ltd, QIAGEN NV, Hologic Inc, bioMerieux SA, DiaSorin SpA, Immunostics Inc., Launch Diagnostics Ltd, Biorex Diagnostics, and ZEUS Scientific are among the key companies operating in the mononucleosis diagnostic market.
The United Nations Children's Fund (UNICEF), National Library of Medicine, Centers for Disease Control and Prevention (CDC), National Institutes of Health, Statistics Canada, Federal Statistical Office (Destatis) are among the primary and secondary sources referred to while preparing the mononucleosis diagnostic market report.
In terms of revenue, North America dominated the mononucleosis diagnostic market in 2023. It is estimated to dominate the global market during the forecast period. The US is the largest market for mononucleosis diagnostics in the world, and it is estimated to dominate the market during the forecast period as well. The mononucleosis diagnostic market growth in the US is attributed to technological advancements, increased awareness, and a constant need for effective disease management strategies. According to the National Institutes of Health, the US records ~125,000 cases of infectious mononucleosis every year.
Owing to such a high number, the awareness of the mononucleosis caused by the Epstein-Barr virus (EBV) is also on the rise in the country, which bolsters the demand for rapid and accurate diagnostic test kits, consumables, and services. Various testing methods adopted by healthcare providers in the country include serological tests based on antibody detection and molecular tests focused on viral DNA identification. The competitive landscape of the mononucleosis diagnostics market in the US is dominated by companies such as Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers. These companies invest in innovation and collaborations to enhance their product offerings and expand their market presence.
Mononucleosis Diagnostic Market Analysis
Development of Point-of-Care Testing to Provide Market Opportunities in Future
POC testing allows for rapid diagnosis at or near the site of patient care, enabling healthcare providers to make immediate clinical decisions and improve patient outcomes. Traditional laboratory tests often require hours or days to generate results, which can delay treatment and worsen symptoms. In contrast, POC tests can deliver results within minutes, facilitating timely intervention. The rapid turnaround is especially crucial for conditions such as mononucleosis, as early diagnosis can reduce complications and enhance patient comfort. POC testing can be implemented in various healthcare settings, including outpatient clinics, emergency departments, and home care settings.
The accessibility is particularly beneficial in areas with limited laboratory infrastructure or in rural regions with insufficient healthcare resources. Bringing diagnostic capabilities closer to patients in the form of POC testing ensures that more individuals receive timely diagnoses and appropriate care, thereby broadening the reach of healthcare services. Moreover, this type of testing promotes greater engagement, as patients can receive their results quickly and discuss the next steps with their healthcare providers.
POC testing can be more cost-effective compared to traditional laboratory testing as they don't need extensive laboratory infrastructure, in turn lowering the overall costs for healthcare systems. The affordability of mononucleosis testing further drives its accessibility to a broader range of patients, especially in underserved populations. Recent advancements in biosensors and microfluidic technologies are driving the development of more sophisticated POC tests with improved sensitivity and specificity.
These innovations ensure the reliability of POC tests in detecting mononucleosis. Mononucleosis diagnostic market players offering POC test kits include SEKISUI Diagnostics (OSOM Mono Test), Abbott (Clearview Mono), and Cardinal Health [Cardinal Health MONO (Mononucleosis) II Rapid Test]. Thus, the development of POC testing generates substantial growth opportunities for the mononucleosis diagnostics market players.
Mononucleosis Diagnostic Market Report Segmentation Analysis
Key segments that contributed to the derivation of the mononucleosis diagnostic market analysis are type and end user.
- Based on type, the mononucleosis diagnostic market is segmented into Epstein Barr Virus antibody test, complete blood count test, and monospot test. The monospot test segment held the largest mononucleosis diagnostic market share of the market in 2023.
- In terms of end user, the mononucleosis diagnostic market is categorized into hospitals, laboratories, and others. The hospitals segment dominated the market in 2023.
Mononucleosis Diagnostic Market: Competitive Landscape and Key Developments
Abbott Laboratories, Arlington Scientific Inc, Bio-Rad Laboratories Inc, Cardinal Health Inc, Meridian Bioscience Inc, Sekisui Diagnostics LLC, Thermo Fisher Scientific Inc, QuidelOrtho Corp, F. Hoffmann-La Roche Ltd, QIAGEN NV, Hologic Inc, bioMerieux SA, DiaSorin SpA, Immunostics Inc., Launch Diagnostics Ltd, Biorex Diagnostics, and ZEUS Scientific are among the key companies operating in the mononucleosis diagnostic market.
The United Nations Children's Fund (UNICEF), National Library of Medicine, Centers for Disease Control and Prevention (CDC), National Institutes of Health, Statistics Canada, Federal Statistical Office (Destatis) are among the primary and secondary sources referred to while preparing the mononucleosis diagnostic market report.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the mononucleosis diagnostic market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the mononucleosis diagnostic market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the mononucleosis diagnostic market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Mononucleosis Diagnostics Market Landscape
5. Mononucleosis Diagnostics Market - Key Market Dynamics
6. Mononucleosis Diagnostics Market - Global Market Analysis
7. Mononucleosis Diagnostics Market Analysis - by Type
8. Mononucleosis Diagnostics Market Analysis - by End User
9. Mononucleosis Diagnostics Market - Geographical Analysis
10. Industry Landscape
11. Company Profiles
12. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
Some of the leading companies in the Mononucleosis Diagnostic Market include:- Abbott Laboratories
- Arlington Scientific Inc
- Bio-Rad Laboratories Inc
- Cardinal Health Inc
- Meridian Bioscience Inc
- Sekisui Diagnostics LLC
- Thermo Fisher Scientific Inc
- QuidelOrtho Corp
- F. Hoffmann-La Roche Ltd
- QIAGEN NV
- Hologic Inc
- bioMerieux SA
- DiaSorin SpA
- Immunostics Inc.
- Launch Diagnostics Ltd
- Biorex Diagnostics
- ZEUS Scientific
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 210 |
| Published | November 2024 |
| Forecast Period | 2023 - 2031 |
| Estimated Market Value ( USD | $ 151.44 Million |
| Forecasted Market Value ( USD | $ 222.15 Million |
| Compound Annual Growth Rate | 4.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 18 |
